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Jlips & Coils 
Treating Brain Aneurysms 
he fall/winter 2003-2004 issue of Focal Spot provided a glimpse 
of the construction—an additional underground vault as well as 
b. control, computer, equipment, and instrument rooms—underway at 
the Scott Avenue Imaging Center in preparation for the delivery of a new mag- 
netic resonance scanner. The massive, ultra-high field (11.75-tesla) scanner 
was recently installed, as shown here, and will aid research in the Biomedical 
Magnetic Resonance Laboratory. 
FOCAL SPOT 
SPRING 2004 
VOLUME 35, NUMBER 1 
OPTICAL IMAGING: SHEDDING LIGHT ON HIDDEN TUMORS 
Researchers in the Optical Radiology Laboratory work with 
high-resolution optical imaging systems interfaced with positron 
emission tomography, computed tomography, and magnetic 
resonance to develop better modalities for diagnosing and 
treating diseases. 
IMPROVING THE ODDS FOR SURVIVING LUNGCANCER 
A National Cancer Institute-funded multicenter 
study comparing the effectiveness of spiral 
computed tomography and chest X-ray screening 
combined with the investigation of advanced 
treatment modalities are part of a joint offensive 
to reduce lung cancer deaths. 
SPOT NEWS 
24 FYI 
CLIPS AND COILS 
A large-scale study shows that patients with 
subarachnoid hemorrhage who live in the St. Louis 
area have a better survival rate because of the 
number of cases treated at Washington University 
Medical Center and the expertise of the Medical 
Center's neuroradiologists and neurosurgeons. 
TRACKING ELUSIVE PROSTATE CANCER 
Two important nuclear medicine studies are 
using positron emission tomography and the 
radiopharmaceutical HC-acetate to diagnose 
recurrent prostate cancer and to determine 
metastases in newly diagnosed, high-risk patients. 
Visit the MIR web site at 
www.mir.wustl.edu 
ON THE COVER Neurosurgeon Ralph Dacey and Intervention^ Neuroradiologist DeWitte 
Cross offer a joint approach to treating subarachnoid hemorrhage by using surgical and 





Kelsey Moran, a fourth- 
year Washington University in 
St. Louis medical student, 
received the 2003-2004 Hugh 
M. Wilson Award for Meritori- 
ous Work in Radiology. The 
award has been presented for 
36 years in honor of Doctor 
Wilson, Mallinckrodt Insti- 
tute's second director and an 
advocate of the advancement 
of education. 
During his radiology rota- 
tion, Moran worked with San- 
jeev Bhalla, MD, assistant 
professor of radiology and 
codirector of body computed 
tomography, on a compilation 
of "CT findings in unilateral 
Glenn/Fontan mimicking pul- 
monary embolisms."  The 
manuscript detailed the diffi- 
culties encountered in using 
computed tomography (CT) 
to detect emboli in the pul- 
monary arteries— because of 
the location in the small or 
medium pulmonary arteries— 
of patients who have had a 
Glenn shunt inserted or have 
undergone the Fontan proce- 
dure to treat tricuspid atresia, 
a congenital heart disease. 
According to Fernando 
Gutierrez, MD, professor of 
radiology, Moran demon- 
strated "his ability to work 
with other departments and 
come up with joint research. 
He worked with Doctor Lud- 
brook [Philip Ludbmok, pro- 
fessor of medicine and of 
radiology, and director of the 
Center for Adults with Con- 
genital Heart Disease], 
putting together the necessary 
clinical data for the manu- 
script, and required very little 
supervision in getting the task 
done." 
New MRI text- 
book available 
Practical Guide to 
Abdominal & Pelvic MRI, a 
new textbook published by 
Iippincott Williams & 
Wilkins, is a handy reference 
for practicing radiologists, for 
residents preparing for board 
examinations, and for MRI 
technologists. According to 
coauthors Jeffrey Brown, MD, 
associate professor of radiol- 
ogy and codirector of mag- 
netic resonance imaging 
(MRI), and former Mallinck- 
rodt Institute Alumnus John 
Leyendecker, MD, assistant 
professor of radiology, Wake 
Forest University Baptist 
Medical Center, Winston- 
Salem, North Carolina, the 
book is a "see what you can 
do" rather than a "see what 
we can do" reference. 
The 268-page book con- 
tains concise descriptions, 
high-quality illustrations, and 
the most common clinical 
cases encountered in daily 
practice. Its four sections 
cover essential physical prin- 
ciples, reviews of specific 
abdominal and pelvic MRI 
examinations, common differ- 
ential diagnoses and aids for 
interpreting preoperative 
imaging studies, and abdomi- 
nal and pelvic MRI anatomy 
reviews. Also included are 
sections covering MRI 
anatomy, terminology, and 




According to a U.S. News 
& World Report survey 
released April 2, 2004, Wash- 
ington University in St. Louis 
School of Medicine (WUSM) 
ranked second in the nation— 
for the second consecutive 
year. Harvard University took 
first-place honors; following 
WUSM were Johns Hopkins 
University, Duke University 
and the University of Pennsyl- 
vania (tie), the University of 
California-San Francisco, and 
the University of Michigan. 
U.S. News & World 
Report initiated the profes- 
sional and graduate school 
rankings in 1987. WUSM annu- 
ally has placed in the top 10 
schools and, since 1998, has 
ranked first in student selec- 
tivity. WUSM departments 
and programs also earned 
high marks: physical therapy 
program ranked second; occu- 
pational therapy, third; pedi- 
atrics and medicine, seventh. 




Since 1985, the Editorial 
Board of Radiology, a leading 
scientific journal, annually has 
honored the most prolific 
manuscript reviewers. The 
recipients of the 2003 Editor's 
Recognition Awards were 
announced in the journal's 
April 2004 issue. Among the 
recipients were the following 
MR faculty: 
With Special Distinction 
• Louis Gilula, MD, professor 
of radiology, of orthopaedic 
surgery, and of plastic and 
reconstructive surgery 
With Distinction 
• Kyongtae Bae, MD, PhD, 
assistant professor of 
radiology and of biomedicil 
engineering 
• David Rubin, MD, associate 
professor of radiology. 






The radiation oncology 
residents annually select the 
Teacher of the Year recipient 
by nominating and voting for 
the faculty member who 
makes a significant contribu- 
tion to radiation oncology res- 
ident education during the 
academic year. The award 
traditionally is presented each 
year in December. 
Carlos Perez, MD, profes- 
sor of radiation oncology and 
chairman of the Department 
of Radiation Oncology, was 
selected as the 2003 Teacher 
of the Year. This is a special 
honor for Perez, as he also 
received the award in 1990. 
He joined the MIR fac- 
ulty in 1964 and was named 
director of the Radiation 
Oncology Center in 1976. In 
June 2001, he was named 
chairman of Washington 
University's newly formed 
Department of Radiation 
Oncology. 
Carlos Perez, MD 
Perez is one of the 
world's most highly regarded 
radiation oncologists and has 
received many honors in 
recognition of his scientific 
contributions, including 
Gold Medal awards from the 
American College of Radiol- 
ogy, the American Society for 
Therapeutic Radiology and 
Oncology, and CRILA/Circulo 
do Radioterapeutas Ibero- 
Latinoamericanos, as well as 
the American Radium Soci- 
ety's Janeway Medal. He is 
coeditor of the textbook 
Principles and Practice of 
Radiation Oncology, now in 
its fourth edition and hailed as 
"the most comprehensive 




Joel Perlmutter, MD, pro- 
fessor of neurology, of neuro- 
logical surgery, and of 
radiology, was named to the 
2004-2005 Marquis8 Who's 
Who in Medicine and Health- 
care. The Marquis Who's Who 
biographical series has been 
published since 1989, and the 
medicine and healthcare vol- 
ume provides information on 
the field's successful educa- 
tors, researchers, clinicians, 
administrators, and industry 
leaders. Perlmutter, who heads 
the Department of Neurology's 
Movement Disorder section, is 
a nationally recognized expert 
in the study of physical and 
chemical factors associated 
with Parkinson disease and 
dystonia. 
In April 2004, Perlmutter 
received the Mentor Award, 
presented by the Washington 
University in St. Louis School 
of Medicine's Academic 
Women's Network. The award 
has been presented annually 
since 1994 to faculty members 
who have served as outstand- 
ing mentors to the University's 





be in St. Louis 
The Society for Molecular 
Imaging (SMI), an international 
scientific education organiza- 
tion, will holds its third annual 
meeting September 9-12, 2004, 
at the Adam's Mark Hotel in 
St. Louis. The key focus of the 
meeting is new insights into 
mammalian biology acquired 
through imaging. Other topics 
include advanced molecular 
imaging approaches in biology 
and medicine, advances in 
positron emission tomography 
and single photon emission 
computed tomography, optical 
tomography and low-light 
imaging, and research and 
industrial collaborations. Early 
discounted registration rates 
are available on or before July 
9, 2004. Register online (with 
credit card) at www.molecu- 
larimaging.org, or call (650) 
216-6621 for more information. 
David Piwnica-Worms, 
MD, PhD, professor of radiol- 
ogy and of molecular biology 
and pharmacology, is SMI 
president and chairman of the 
meeting. Joseph Ackerman, 
PhD, professor of chemistry, 
of medicine, and of radiology, 
and chief of the biomedical 
magnetic resonance imaging 
laboratory, and Michael Welch, 
PhD, professor of radiology, 
of chemistry, and of molecular 
biology and pharmacology, 
and cochief of the Division of 





In June, 19 physicians 
will begin their first year of 
training in diagnostic radiol- 
ogy. These promising trainees 
come to MIR from excellent 
medical schools: Emory Uni- 
versity (2); Harvard University 
(2); New York University (1); 
University of California, San 
Francisco (1); University of 
Iowa (1); University of 
Louisville (1); University of 
Pennsylvania (2); University 
of Washington (1); University 
of Wisconsin (1); Washington 
University in St. Louis (6); 
Yale University (1). 






&  ^9b t on  Hidden  Tumors 
THE LIGHT WE DON'T SEE CAN SAVE OUR LIVES. 
B
 t's absolutely amazing what we can do with light. In the visible light range, 400 to 750 nanometers 
- (1 billionth of a meter), humans have body tissues that attract and absorb light: melanin, proteins, am 
oxyhemoglobin. This propensity for selective tissue absorption has led to the development of lasers for hai 
removal, spider vein dissolution, treatments for the rosacea "blush" of adult acne, and even removal of ad 
spots—all very popular procedures with people needing these services. While these breakthroughs are valuabll 
in themselves, light and optical imaging have now moved into important diagnostic and therapeutic realms. 
MARY    JO    BLACKWOOD,    RN,    MPH,    CHES 
Near-Infrared Imaging 
To look deeper into our bodies 
for the secrets of diagnostic and 
healing applications, we have to 
move away from the visible light 
range, away from the surface 
attractants. Samuel Achilefu, PhD, 
is interim chief of the Optical 
Radiology Laboratory at Mallinck- 
rodt Institute of Radiology (MIR). 
His work revolves around the 
diagnostic applications of the 
near-infrared spectrum of light in 
the 750 to 900 nanometer range. 
Researchers in the Optical 
Radiology Laboratory (ORL), 
established in 1999, work with 
high-resolution optical imaging 
systems. "We are gradually assem- 
bling the personnel and equipment 
we need. It takes a combination of 
several different technologies," 
says Achilefu, an associate profes- 
sor of radiology. "Using optical 
spectroscopy in the visible wave- 
lengths, we can penetrate only a 
few millimeters into tissues. 
However, when we perform 
optical imaging through diffused 
optical tomography, we can delve 
several centimeters into tissue, 
depending on the instrument and 
methodology." 
In biological systems, 
researchers have found that light 
absorption and scattering are 
in the right interpretive 
modes, indicative of physio- 
logic states. Research on the 
brain with optical imaging 
has shown that hemoglo- 
bin spectroscopy of the 
different brain regions 
can reveal internal bleed- 
ing caused by head 
injury. In the breast, 
increased blood volume 
or vascularity can pin- 
point tumors. 
TO look deeper into our bodies... 
we have to move away from the visible light range, away 
from the surface attractants. 
How Optical 
Imaging Works 
As Achilefu explains, light scat- 
ters when it hits tissue. Computer 
algorithms can correct for the scat- 
tering. An algorithm is a formula or 
set of rules for solving a particular 
problem—in this case, where the 
light would have gone had it not 
scattered. Using these algorithms 
to reconstruct the path of light 
after scattering can create slices of 
tissue as would a computed tomog- 
raphy (CT) scan or a magnetic 
resonance imaging (MRI) scan. 
"The optical methods 
are highly sensitive 
and can 
detect minute 
amounts of light-sensitive materi- 
als. In this lab, we are developing a 
state-of-the-art diffuse optical 
tomography, or DOT, system and 
molecular beacons to use as a con- 
trast agent for optical imaging. We 
now have the ability to study brain 
function, angiogenesis, and protein 
expression in tumors as well as 
metastases," says Achilefu. 
As principal investigator, 
Achilefu received a National Insti- 
tutes of Health-funded project to 
interface optical imaging and 
positron emission tomography 
■   ■  ■  ■  ■ 
(Left to right) Researchers Sachin Patwardhan, 
Sharon Bioch, and Joseph Culver are shown with a 
diffused optical tomography (DOT) system devel- 
oped and built in the Institute's Optical Radiology 
Laboratory. 
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Opt Imaging 
(PET) imaging into a hybrid tech- 
nology. Barry Siegel, MD, chief of 
the Division of the Division of 
Nuclear Medicine, and Michael 
Welch, PhD, cochief of the Division 
of Radiological Sciences, are active 
collaborators on the research. "We 
still have the problem of localiza- 
tion in deep tissue by optical meth- 
ods. That's where PET comes in," 
says Achilefu. "We use PET to 
map the area to get a baseline. 
Then we can monitor the 
status of the disease 




in the near-infrared region after the 
PET radioisotope decay. An advan- 
tage of optical imaging is that it is 
nonionizing, or nonradioactive." 
Another promising interface is 
between CT or MFJ scanning and 
optical imaging. CT has a high 
structural resolution; optical imag- 
ing delivers high functional infor- 
mation. According to Achilefu, CT 
will be performed in conjunction 
with optical imaging soon in 
humans. The imaging techniques 
scan the same tissue but are asking 
different questions. "CT asks 
where the margins of the 
tumor are. Optical interro- 
gates the functional sta- 
tus of the cells at the 
margins. When patients 
with cancer are treated, 
we sometimes have to 
wait for months to observe 
the effectiveness of the 
treatment regimen, which 
can be manifested by 
reduction in tumor 
size, as evidenced 







tumors to treat- 






speeds up the 
process of find- 
ing effective 
interventions." 
The Future of 
Optical Imaging 
On a list of potential applications 
for optical imaging are brain function 
and cervical, colon, gastrointestinal 
(GI), prostate, and breast cancer, 
which present viable targets by non- 
invasive DOT or endoscopy. "Nonin- 
vasive breast imaging or 
spectroscopy in the MR [near- 
infrared] wavelengths is particularly 
attractive; because of the breast's 
anatomy, a probe can be placed 
around it and iUumination can be 
obtained from multiple directions: 
up, down, side-to-side, frontally. We 
can triangulate images and get much 
better three-dimensional identifica- 
tion," explains Achilefu. "In contrast, 
imaging deep organs noninvasively, 
such as the liver, is a challenge 
because of the attendant poor image 
resolution that results from multiple 
light scattering in deep tissues. We 
currently cannot scan different 
views of such organs by optical 
methods. Researchers in the ORL 
are working now on validation stud- 
ies using small animals. In two years, 
we hope to be doing clinical testing 
with patients." 
According to Achilefu, unlike 
MRI or PET, which use radioactive 
tracers, optical equipment does not. 
"Optical imaging can be performed 
safely in a physician's office and 
organ function can be monitored in 
real time. It is an exciting area" 
He is especially interested in 
combining the diagnostic and thera- 
peutic potential of optical methods. 
"Optical methods give us the oppor- 
tunity to 'see and treat' diseases. The 
treatment arises from substances 
that are triggered by light to destroy 
only the diseased cells where it is 
Samuel Achilefu is shown in the Optical Radiology Laboratory, in an area 
where researchers work on systems to combine magnetic resonance and 
optical imaging. 
MALLINCKRODT INSTITUTE OF RADIOLOGY 
localized," says Achilefu. "This 
approach is called photodynamic 
therapy. In the ORL, we are develop- 
ing these dual-role materials, which 
can be used to perform both imaging 
and treatment. I call these drugs 
'diapeutics,' an acronym for combin- 
ing diagnostic and therapeutic 
effects into one drug." 
"The longer the wavelength, the 
lower the energy," he adds. "Diapeu- 
tics have two components that can 
absorb two different wavelengths. 
Activation of the drug at a longer 
wavelength helps the physician dis- 
cern the exact nature of the problem 
without distracting surface absorp- 
tions. Then the light of a shorter 
wavelength can be used to treat the 
diseased tissue, working by photo- 
sensitive molecular excitation. Light 
of the appropriate wavelength pro- 
duces free radicals that are toxic to 
surrounding cells. At some point, we 
will be able to do diagnosis and treat- 
ment by optical methods alone." 
In the field of biological imaging, 
Mallinckrodt Institute's ORL is mov- 
ing toward complete integration of 
multiple modes of imaging. Joseph 
Culver, PhD, an expert in DOT, 
recently joined the ORL and will play 
a vital role in the development of 
highly sensitive DOT systems. DEI 
The ORL will play a major role in Biomed 21, Washington University School 
of Medicine's strategic plan for developing a multidisciplinary approach to 
basic and clinical research. Named for its potential for advancing research 
and clinical practice in the 21s' century, BioMed 21 will include components 
such as the Genome Sequencing Center, The Genome Sciences and 
Human Genetics Program, the Division of Clinical Sciences, and the Center 
for Biological Imaging—where the ORL will shine. 
Optical Imaging Laboratory 
Samuel Achilefu, PhD, associate professor of radiology 
and interim laboratory chief 
Mikhail Berezin, PhD, research associate 
Sharon Bloch, PhD, research associate 
Joseph Culver, PhD, assistant professor of radiology 
Kexian Liang, research technician 
Nancy North, secretary 
Sachin Patwardhan, PhD, research associate 
Yunpeng Ye, PhD, research associate 
Zongren Zhang, PhD, research associate 
Achilefu and his colleagues are closely 
watching research at Johns Hopkins 
and Clemson universities where light 
absorbing and scattering parameters 
are being used as a noninvasive 
approach to distinguishing between 
breast cancers and benign tumors like 
fibroadenomas. Watch for more infor- 
mation in upcoming issues of Focal 
Spot magazine. 
% 
A closer look at the prototype DOT system to 
detect brain function and certain types of cancer. 
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Improving the Odds for 
Surviving Lung Cancer 
IMAGING AND COLLABORATION ARE KEY TO IMPROVING SURVIVAL RATES 
/ 


































THE TECHNOLOGY-FUELED WAR AGAINST LUNG CANCER IS HEATING UR 
UNLIKE MANY OTHER CANCERS, ITS DEATH RATES HAVE NOT DECLINED. REDUCING THE TOLL 
OF THIS DEVASTATING DISEASE CAN ONLY HAPPEN WITH A JOINT OFFENSIVE IN DIAGNOSIS AND 
TREATMENT. MALLINCKRODT INSTITUTE OF RADIOLOGY (MIR) AND THE DEPARTMENT OF 
RADIATION ONCOLOGY ARE PARTNERS IN THIS FIGHT, EACH CONTRIBUTING RESEARCH AND 
CONSULTATION TO THE OTHER FOR ENHANCED RESULTS. 
IMPORTANCE OF 
EARLY DETECTION 
Experience tells us that the 
earlier a catastrophic condi- 
tion is detected, the more 
treatable it is and the better the 
outlook for cure. The rub comes in 
how we define "early." Concerning 
lung nodules, early can have sev- 
eral meanings: still small in size, 
confined to one area, or at an 
early stage. In 15 percent to 30 
percent of the cases, by the time 
symptoms have led to detection, 
the cancer has already spread 
outside the lung. 
NATIONAL LUNG 
SCREENING TRIAL 
The National Lung Screening 
Trial (NLST) began in 2002, 
with a goal of comparing spi- 
ral computed tomography (CT) and 
chest X-ray screening for their 
effectiveness in reducing deaths 
from lung cancer. The NLST 
involves 30 sites across the country 
and combines data collected from 
the Prostate, Lung, Colorectal and 
Ovarian (PLCO) trial network that 
started 10 years ago and the Ameri- 
can College of Radiology Imaging 
Network (ACRIN). 
David Gierada, MD, an associ- 
ate professor of radiology with 
expertise in chest radiology and CT 
imaging, is coprincipal investigator 
for the NLST at Washington Univer- 
sity in St. Louis. He reports that the 
enrollment of 50,000 former or 
current smokers nationally was 
reached in February 2004— 
more than six months ahead of 
schedule. The St. Louis site has 
3,800 participants enrolled. 
Eligible participants are ran- 
domly assigned to receive either a 
chest X ray or a spiral CT scan. 
They receive an initial screening, 
with a repeat screening at years 
one and two. Then participants 
will receive follow-up tracking 
through 2009. 
"Spiral CT allows identification 
of lung nodules at a smaller size 
than a chest X ray does, but we 
don't know whether these patients 
will survive longer. We expect the 
smaller tumor to be more treat- 
able," says Gierada. "However, not 
all small tumors exhibit the same 
behavior. Some small tumors can 
spread early. Other tumors have a 
very slow growth rate; so even if 
they go undetected, they may not 
result in the patient's death, analo- 
gous to what is often observed with 
prostate cancer. 
In addition to tumor size, the 
study gathers data on nodule 
characteristics and the staging of 
known cancers, which takes into 
account not only tumor size but 
lymph node involvement and any 
detected distant metastases. The 
higher the stage, the worse the 
survival outlook. Given all those 
tumor variables, and the fact that 
only a small percentage of NLST 
participants are expected to die 
from lung cancer during the course 
of the study, the NSLT is looking 
for data from the 50,000 partici- 
pants to determine whether one 
type of screening is more effective 
than the other at reducing lung 
cancer deaths. 
In the NLST, if participants 
have positive screenings (denned 
as a nodule equal to or greater than 
4 millimeters) that information is 
given to the patients and their 
primary physicians with recom- 
mendations for follow-up care. 
Unanswered questions still exist 
because most nodules are not can- 
cerous. All positive test results are 
followed up to determine outcome. 
One option for patients is to be 
seen in the Surveillance of Pul- 
monary Indeterminate Nodules 
(SPIN) clinic. Patients may self- 
refer or be referred by their attend- 
ing physicians. Nearly half of the 
FOCAL SPOT, SPRING 2004 
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Improving the Odds for 
Surviving Lung Cancer 
SPIN clinic patients come from the 
NLST. Patients are seen by Wash- 
ington University thoracic surgeons 
and advanced nurse practitioners 
experienced in dealing with the 
issues. "We can do further testing 
with a variety of radiological tech- 
niques to help distinguish malig- 
nant tumor from benign nodule. 
If the nodule is cancerous, we 
assist in staging and identifying 
the appropriate treatment options," 
says Gierada. 
chest radiograph (Fig. A) and low dose -. 
scan (Fig. B) show lung cancers detected in two 
National Lung Screening Trial participants at Washing- 
ton University in St. Louis. The right lung lesion i 
chest radiograph measures 2 cm in diameter; tu 
'on on the CT scan measures 1 cm in di 
Study participants return annu- 
ally for screening and/or to update 
their medical history: What they 
did about the test's positive results, 
whether follow-up care resulted in 
a diagnosis of lung cancer, and    , 
what treatment they had. In addi- 
tion to detecting cancer early, an 
important objective of the study is 
to minimize the number of proce- 
dures done on benign lesions. 
There are additional benefits 
of the NLST. All the generated data 
can be used to determine what 
features of the identified nodules 
make them more or less likely to 
be malignant, such as the behavior 
of different sizes and shapes of 
nodules in different parts of the 
lung. The CT image data will be 
available to researchers through a 
centralized library, containing all 
CT scans performed at PLCO 
screening centers, and will be 
located and managed in MIR's 
Electronic Radiology Laboratory. 
COORDINATION OF DIAGNOSIS 
AND TREATMENT 
For patients who are diagnosed 
with lung cancer and will be 
treated at the Washington Univer- 
sity Medical Center, a multidiscipli- 
nary group meets weekly to discuss 
possible treatment plans. Thoracic 
surgeons, medical oncologists, 
pathologists, radiation oncologists, 
and diagnostic radiologists all col- 
laborate. When a case is presented, 
all group members contribute their 
data and discuss appropriate treat- 
ment. Diagnostic radiology plays an 
important role in helping to stage 
a tumor by employing a variety 
of techniques and directing treat- 
ment options. 
IF THE NODULE IS 
CANCEROUS, WE 
ASSIST IN STAGING AND 
IDENTIFYING THE APPRO 
PRIATE TREATMENT OPTIONS. 
TREATING LUNG CANCER 
The second critical piece in the 
war on lung cancer is the advance- 
ment of treatment modalities, 
particularly in the area of radiation 
therapy. According to Jeffrey 
Bradley, MD, assistant professor of 
radiation oncology, most patients 
with lung cancer benefit more from 
surgery. If the tumor is not opera- 
ble, then radiation treatment is 
increasingly a good choice. 
Approximately three fourths of 
patients with lung cancer will need 
radiation treatment, with or with- 
out surgery. The Department of 
Radiation Oncology offers the lat- 
est in imaging and treatment for 
lung cancer. Three-dimensional 
conformal radiation therapy (3D- 
CRT), using a combined positron 
emission tomography (PET) and 
CT scanner, allows clinicians 
simultaneously to localize and tar- 
get lung cancers more accurately 
and to deliver more effective doses 
of radiation to the tumor, while 
sparing adjacent healthy tissue. 
10 MALLINCKRODT INSTITUTE OF RADIOLOGY 
Hi 
"PET/CT is ideal for radia- 
tion planning," says Bradley, 
who sees patients at Siteman 
Cancer Center in the Center for 
Advanced Medicine. "Before 
three-D-CRT technology, treat- 
ment was more for symptom 
control than for cure. Parts of 
the tumors often received lower 
doses of radiation in order to 
spare healthy tissue nearby. 
We've found that since the 
development of three-D 
conformal therapy in the 1990s, 
delivery of radiation specifically 
to the tumor has been improved. 
And with small inoperable 
tumors, we may be achieving a 
higher cure rate, which has led 
to more aggressive treatment." 
Bradley is basing this infor- 
mation on his retrospective 
study of 207 patients treated at 
Washington University Medical 
Center with 3D-CRT between 
1991 and 1998. "For a patient 
with lung cancer whose tumor 
isn't treated with surgery, the 
traditional staging system may 
not be the right approach. Based 
on our findings, total tumor vol- 
ume may be more important," 
he says. 
Tumor volume refers to the 
total size of the tumor and any 
affected lymph nodes. When the 
study data was analyzed, age, 
tumor stage, and any adjunct 
chemotherapy were dropped 
out of the equation, leaving total 
tumor volume. The average sur- 
vival rate for the 207 cases with 
CAD Differentiates Lung Nodules 
T 
At Mallinckrodt Institute of Radiology, computer- 
aided diagnosis (CAD) is being used to aid in the 
automated detection and characterization of 
lung nodules and focal ground-glass opacities [nonsolid 
opacities]. Ty Bae, MD, PhD, associate professor of radiology, 
is at the forefront of this research. He sees CAD as an aid to 
the skilled radiological practitioner, contributing in four main 
areas to lung cancer diagnosis: 
> Computer algorithms simulate the human detection process. The algorithm is a set 
of rules or steps a programmer designs, a decision tree that allows the program to do the job it is 
designed to perform. Says Bae, 'There are certain radiological tasks that computers can do better 
than humans, like measuring area and volume, and having an almost unlimited ability to remem- 
ber numbers and images from a previous study for comparison to the current study. But beyond 
that, the experienced radiologist is probably better overall at performing most diagnostic tasks." 
> Consistent performance. Even skilled radiologists have a fatigue factor when going 
through hundreds of images to detect small modules. "If a radiologist reviews twenty cases in a 
day, he or she has to scrutinize a couple thousand images and has to detect and document 
nodules and other findings seen in each image. With CAD integration, the computer can help 
flag and document nodules for the radiologists, thus improving their diagnostic performance and 
work flow. The computer has been over ninety percent successful in identifying very small lesions, 
and it has no fatigue factor," says Bae. 
The lung is a unique organ because it is full of air, which provides a good contrast to soft tissue. 
Within the lung tissue, structures are either vessels or nodules. "With CT scans, we are looking at 
very thin cross-sectional slices of the chest cavity. The pulmonary vessels are typically perpendicular 
to the image plane. On each image, a nodule is round, and so is a cross section of an artery. We 
differentiate the nodule and vessel by visually examining the structural continuity between adjacent 
slices. Our CAD system can easily track lung structures and evaluate their three-dimensionality 
mathematically, separating the nodules from the vessels over multiple slices," explains Bae. 
> Nodule characteristics. Says Bae, "After a nodule is identified, then we must determine the 
characteristics that make it more or less likely to be cancerous. For instance, we look at calcifica- 
tion. If the nodule is completely calcified, it is benign. Unfortunately, most nodules are indetermi- 
nate without definite morphologic signature, so we repeat the CT scan after some time interval to 
follow their growth pattern. Rapid growth usually means cancer. The CAD program measures 
the difference in nodule volumes between the initial and follow-up CT scans and may detect early 
growth not obvious to the human eye—then the radiologist can act on it more quickly." 
> Reporting speed. "After the detection, CAD can facilitate reporting the three-dimensional 
location and volume over many slices, time and time again—much more quickly than a human 
can," say Bae. 
Bae and his research team is currently developing the tools needed for small-scale clinical 
studies at Mallinckrodt Institute in 2005 to evaluate the utility of CAD for improving the detection of 
lung nodule and focal ground-glass opacities. 
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Improving the Odds for 
Surviving Lung Cancer 
all tumor sizes treated with 3D-CRT 
was 59% after one year and 41% 
after two years. Patients with 
tumor volumes of three cubic cen- 
timeters or less had a tumor-spe- 
cific survival rate of 78% for both 
year one and year two, as com- 
pared with 51% after year one and 
29% after year two for those 
patients with the largest tumors. 
Bradley's study indicated that 
3D-CRT may be a good alternative 
for patients whose tumors could be 
surgically treated but for whom 
surgery itself would be risky. It also 
suggested that patients with large 
tumors should be treated less 
aggressively, using radiation for 
symptom control. 
Another treatment that shows 
great promise, according to 
Bradley, is the use of stereotactic 
high-dose radiation for patients 
who are prescribed a combination 
of surgery and radiation. Stereo- 
tactic radiation involves a number 
MOST PATIENTS WITH LUNG CANCER BENEFIT 
MORE FROM SURGERY. IF THE TUMOR IS NOT OPERABLE, 
THEN RADIATION TREATMENT IS INCREASINGLY A GOOD CHOICE. 
APPROXIMATELY THREE FOURTHS OF PATIENTS WITH LUNG CANCER 
WILL NEED RADIATION TREATMENT, WITH OR WITHOUT SURGERY. 
of precisely aimed beams of ioniz- 
ing radiation—each coming from 
different directions and meeting at 
a specific point—to deliver the 
radiation dose. "In order to deliver 
a stereotactic dose, lung movement 
during breathing must be con- 
trolled. The Department of Radia- 
tion Oncology has new equipment 
that immobilizes the chest and 
allows only shallow breathing for a 
short period. We plan to start treat- 
ing patients with this technique 
soon, but still utilize the targeted 
three-D-CRT approach. It's the 
most technologically advanced 
form of three-D-CRT," he says. 
Physicians in Japan and 
Germany have been using the 
technique for five years, and the 
reports are encouraging. "Physi- 
cians at the University of Indiana 
and at other medical facilities 
have begun treating patients with 
this technology. The Radiation 
Therapy Oncology Group (RTOG) 
is starting a long-term trial involv- 
ing ten to twenty institutions to 
track the procedure's effective- 
ness," says Bradley, who received 
his 3-D training in Germany. 
Other areas being explored 
are 4D-CT simulations that con- 
trol lung motion during breathing 
and can deliver a burst of radia- 
tion during the same position in 
the respiratory cycle. Says 
Bradley, "Everything we do in 
the Department of Radiation 
Oncology is based on imaging." 
Add the early detection 
technology being investigated 
at Mallinckrodt Institute of 
Radiology to the Department 
of Radiation of Oncology's 
image-based treatment modali- 
ties, and this war on lung cancer 
could be won. EM 
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> Lung cancer is the leading 
cause of cancer death in both 
men and women in the United 
States. 
> Lung cancer is the ITlOSt 
preventable type of cancer. 
> Smoking cigarettes, cigars, or a 
pipe is the number one 
Cause of lung cancer; smoking 
accounts for 87% of lung cancers. 
The longer a person has smoked 
and the more cigarettes smoked 
per day, the greater the risk of 
developing lung cancer. 
> The incidence for lung cancer in 
African-American males is 
approximately 50 percent 
higher than in their white coun- 
terparts; the death rate is 27 
percent higher. 
> An estimated 174,000 people 
in the United States will be 
newly diagnosed with lung 
cancer in 2004. 
> An estimated 160,000 people 
in the United States will die from 
lung cancer in 2004—approxi- 
mately 92,000 males and 68,000 
females. 
> There are two major types of lung 
cancer: non-Small cell (more 
common, usually metastasizes 
more slowly) and small cell 
(also called oat cell). Small cell 
lung cancer accounts for approxi- 
mately 20 percent of all lung 
cancers and is usually caused by 
smoking. 
> Depending on the type and stage, 
lung cancer is usually treated by 
surgery, radiation therapy, or 
chemotherapy—either alone 
or in combination. 
> The number of Americans getting 
lung cancer is decreasing, 
primarily due to the decrease 
in adult smoking over the past 
30 years. 
> Smoking among teenagers and 
adolescents has increased in 
recent years. The increase 
can cause a potential rise in lung 
cancer incidence in future years 
as this population ages. 
> Early-stage lung cancer 
usually does not cause 
Symptoms. The following 
symptoms may occur but may 
not indicate lung cancer and 
could be signs of a less serious 
disease. If you do have these 
symptoms, see your physician 
for a proper diagnosis. 
1. chronic cough 
2. repeated bouts of pneumonia 
or bronchitis 
3. hoarseness 
4. weight loss/loss of appetite 
5. shortness of breath 
6. wheezing 
7. chest pain 
8. coughing up blood 
> Risk factors for lung cancer 
include tobacco use, secondhand 
smoke, personal and family his- 
tory, gender, and cancer-causing 
agents such as arsenic, asbestos, 
or radon. 
This information was excerpted from several sources, including the American Cancer Society 
and the American Lung Association. If you would like to read more about lung cancer, check 
out the following web sites: 
American Cancer Society—www.cancer.org 
Alliance for Lung Cancer, Advocacy, Support & Education—www.alcase.org 
American Lung Association—www.lungusa.org 
American Medical Association—www.ama-assn.org 
National Cancer Institute—www.nci.nih.gov 
National Heart, Lung, and Blood Institute—www.nhlbi.nih.gov/index.htm 
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Clips // Coils 
High-volume centers show results in treatment of 5AH 
CAN BE A VIOLENT ASSAILANT. TYPICALLY 
CAUSED BY A RUPTURED ANEURYSM-A WEAK SPOT IN A BRAIN BLOOD VESSEL THAT BLEEDS INTO THE SPACE 
BETWEEN THE BRAIN AND SKULL-SAH AFFECTS THOUSANDS OF AMERICANS EACH YEAR AND, IN MANY CASES 
RESULTS IN DEATH OR PERMANENT BRAIN OR NERVE DAMAGE. 
A LARGE-SCALE STUDY LED BY DEWITTE CROSS, MD, ASSOCIATE PROFESSOR OF RADIOLOGY, OFFERS NEW HOPE T 
PATIENTS WITH SAH, ESPECIALLY THOSE LIVING NEAR "HIGH-VOLUME" MEDICAL CENTERS. AS IS TRUE WITH MAN 
TYPES OF MEDICAL AND SURGICAL :E MORE SAH CASES TREATED AT A FACILITY, THE BETTER THE 
OUTCOMES TEND TO BE. BUT CROSS, iTERVENTIONAL NEURORADIOLOGY AT MALLINCKRODT 
INSTITUTE OF RADIOLOGY, AND THE MULTIDISCIPLINA EAM WERE STRUCK BY THE DRAMATIC IMPROVE- 
MENT IN SAH-RELATED MORTALITY RATES BETWEEN HIGH-VOL       LOW-VOLUME CENTERS. 
'.»! 
Study results 
In a retrospective study of 
more than 16,000 hospital admis- 
sions for SAH in 18 states, the 
researchers concluded that 
hospitals treating more than 35 
SAH cases per year had a 40 per- 
cent lower mortality rate than 
did those hospitals treating less 
than 10 cases. And this is good 
news for St. Louis area-residents: 
Barnes-Jewish Hospital at Wash- 
ington University Medical Center 
ranks among the high-volume 
centers, with about 150 admis- 
sions for SAH per year and about 
200 patients with ruptured and 
unruptured cerebral aneurysms 
treated annually. 
Specific causative factors 
could not be identified by the study 
data, but Cross believes several 
factors found at high-volume 
centers contribute to the improved 
SAH mortality rates. 
♦ Large tertiary centers such as 
Barnes-Jewish Hospital offer a 
wider array of both surgical and 
noninvasive techniques and 
strategies. 
♦ The centers have experienced 
neurosurgeons, interventional 
radiologists, and support staff. 
♦ Physicians have access to the 
latest advances in diagnostic 
and treatment technology. 
According to Cross, 
Washington University Medica 
Center has another advantage: 
a tremendous level of interde- 
partmental cooperation. And 
this is extremely important in 
cases, such as SAH, where 
there are two possible treatme 
options—one surgical, the 
other endovascular. 
The Cerebral Aneurysm Treatment Team: (left 
right) doctors Christopher Moran, DeWitte Cri 
and Colin Derdeyn—neuroradiology; Ralph D( 
Robert Grubb, and Michael Chicoine—neurolo 
surgery. Not shown are doctors Keith Rich, C 
gory Zipfel, and Joshua Dowling—neurologic 
surgery; and Michael Diringer and Venkatesh 
Aiyagari—neurology; and Tracy Dobbie, RN. 
Clips     Coils 
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Causes of SAH 
Initially, there are two types of 
SAH cases: traumatic and sponta- 
neous. Traumatic SAH is caused 
by an injury—in the United States, 
mostly from bicycle, motorcycle, 
or automobile accidents. Accord- 
ing to the Brain Injury Association, 
approximately 373,000 people 
are hospitalized annually with 
brain injuries. 
Spontaneous SAH is usually 
caused by the rupturing of an 
aneurysm and occurs most fre- 
quently in people between the ages 
of 35 years to 65 years. Weakening 
of the vessel wall can occur even in 
healthy people, but some common 
risk factors include smoking, high 
blood pressure, head trauma, and 
alcohol abuse. About two million 
Americans have brain aneurysms, 
and most of these aneurysms 
remain undetected and cause no 
harm. However, statistics show 
there are about 30,000 ruptured 
aneurysms every year in the United 
States. About half of those cases 
result in death caused by the sud- 
den increase in pressure on the 
brain, resulting from the flow of 
Colorized 3D angiogrophic renderings of an anterior 
communicating aneurysm. 
blood into the subarachnoid space. 
The pressure cuts off blood supply 
to the brain. 
SAH survivors face a troubling 
prognosis: a recurrence of bleeding 
or other complications (resulting in 
a 50 percent mortality rate) or 
debilitating impairments affecting 
motor skills, vision, speech, or 
mental function. But these grim 
outcomes are dramatically 
improved if SAH, and the culprit 
aneurysm, can be diagnosed and 
treated quickly. 
Treatment options 
At Washington University Med- 
ical Center, patients with suspected 
SAH typically come first to the 
Charles F. Knight Emergency Cen- 
ter. Patients describe the headache 
pain typical of the SAH attack as 
the worst pain they have ever expe- 
rienced. They may also suffer dis- 
orientation, vomiting, and loss of 
consciousness. Patients are evalu- 
ated immediately either by a com- 
puted tomography (CT) scan or 
spinal tap to confirm the SAH, then 
by a cerebral angiogram to locate 
the aneurysm. 
The next step involves the joint 
effort of interventional neuroradiol- 
ogists and neurosurgeons like 
Cross and Ralph Dacey, MD, 
professor of neurosurgery and 
chairman of the medical school's 
Department of Neurological 
Surgery. Here the interplay of 
experience, access to and knowl- 
edge of the latest technology, and 
cooperation among disciplines 
work to determine the best course 
of action— surgical or noninvasive. 
Surgeons can perform a clip litiga- 
tion (opening the skull and using a 
clip to close the offending 
aneurysm); interventional neurora- 
diologists can use a catheter and 




Cross explains the importance 
of teamwork at Washington Univer- 
sity Medical Center: "One of our 
strengths in this field is our joint 
approach to SAH treatment, with 
the sole concern of what is best for 
the patient. Some patients are not 
candidates for noninvasive treat- 
ment, and surgery is the best 
option. But we have to act 
quickly—the sooner the bleeding 
is controlled, the less likely the 
chance of recurrence." 
To decide which option is 
appropriate for a particular patient, 
the team evaluates four factors: 
location of the aneurysm, its 
shape, the clinical grade of the 
patient, and patient preference 
(if the patient is conscious 
and able to participate in the 
treatment choice). To date, 
about half of the SAH cases 
have been treated surgically. 
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A noninvasive choice 
The remaining 50 percent of 
cases have undergone endovascular 
coil embolization, a relatively new 
and minimally invasive radiology 
procedure benefiting from 
advances in microcatheter technol- 
ogy. Endovascular coil emboliza- 
tion uses tiny tubes inside arteries 
(microcatheters) to enter and treat 
the aneurysms. To treat SAH, the 
patient undergoes general anesthe- 
sia. A neuroradiologist threads a 
catheter through the femoral artery 
in the groin, making a small incision 
at the insertion site. This thin tube 
is maneuvered directly into the site 
of the ruptured aneurysm, using 
angiography during the procedure 
to guide the catheter. Angiography 
uses an injected contrast, which 
flows into the arteries, mapping the 
blood flow out of the rupture. 
"These 'maps' are made even 
clearer by the use of advanced 
angiography, which gives us bipla- 
nar images during the procedure," 
says Cross. "I can see the catheter, 
the aneurysm, and the artery 
in several relational views as I 
am working." 
Ralph Dacey, MD, (right) and a neurological 
surgery team 
esource 
THE FOLLOWING LISTING DOES NOT IMPLY MALLINCKRODT 
INSTITUTE'S ENDORSEMENT OF THESE WEB SITES' CONTENT 
BUT IS INTENDED SOLELY FOR GUIDANCE ON WHERE TO BEGIN 
YOUR SEARCH FOR SAH INFORMATION. 
AMERICAN SOCIETY OF NEUR0RADI0L0GY (WWW.ASNR.ORG) 
AMERICAN ASSOCIATION OF NEUROLOGICAL SURGEONS 
(WWW.AANS.ORG) 
AMERICAN SOCIETY OF INTERVENTIONAL AND THERAPEUTIC 
NEUR0RADI0L0GY (WWW.ASITN.ORG) 
BRAIN INJURY ASSOCIATION (WWW.BIAUSA.ORG) 
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Next, tiny platinum coils are fed 
into the rupture to block the flow of 
blood. Platinum is used because the 
material does not interfere with the 
magnetic forces used in many imag- 
ing procedures, such as magnetic 
resonance imaging. Coils range in 
size from two to 20 millimeters in 
diameter and come in many shapes. 
They are inserted into the catheter 
as straight sections and curl up into 
their initial shape when deployed, 
then they are detached in the 
Interventional Neuroradiologist DeWitte Cross 
prepares to insert an arterial catheter, to begin 
an endovascular aneurysm treatment procedure. 
aneurysm using a minute jolt of 
electrical current. Imagine 
stretching a Slinky® (the wire toy 
that's been around since 1945) until 
it is straight, then letting it go— that 
is a platinum coil, enlarged many 
times over. 
Cross explains the finesse 
involved in this procedure: First, a 
'basket' with a complex coil shape is 
created within the aneurysm; then, 
helical-shaped coils are placed 
inside until the bleeding is con- 
trolled. "That's another advantage of 
being a high-volume treatment cen- 
ter, we have a large supply of vari- 
ous coil shapes and sizes," he says. 
When the neuroradiologist is 
satisfied with the coil arrangement, 
the catheter is withdrawn and the 
small incision is sutured. The 
patient is taken to the hospital's 
Intensive Care Unit to be moni- 
tored for at least 24 hours and may 
be ready to return home as early as 
the next day in electively treated 
cases, while patients with SAH 
remain in the hospital longer for 
full recovery. With the surgical 
treatment, a longer hospital stay 
and significantly longer time to full 
recovery is required for elective 
aneurysm treatment. 
Cross emphasizes that coils are 
not appropriate in every case. The 
re-treatment rate following the 
coils procedure is 10 percent, as 
compared to two percent for surgi- 
cal clipping—so aneurysms that 
can be treated surgically with low 
rates of morbidity are often 
(A and B) Left middle 
cerebral aneurysm 
before and after 
clipping. 
(C and D) Anterior com- 
municating aneurysm 
before and after coiling. 
clipped. However, there are advan- 
tages to the coil procedure in 
aneurysms that are difficult to treat 
surgically, including lower risks of 
permanent disability and lower 
mortality. The British medical jour- 
nal Lancet reported in a 2002 multi- 
center study, mainly of anterior 
communicating aneurysms, that 
coiling resulted in a 22.6 percent 
reduction in the relative risk of dis- 
ability or death over the neurosur- 
gical clipping procedure. 
21st century training 
MIR's interventional neuroradi- 
ology fellowship program is train- 
ing the next generation of 
specialists who will learn even bet- 
ter techniques and procedures. 
Equally important, says Cross, is 
that these trainees learn the impor- 
tance of cooperation among disci- 
plines and cross-specialization in 
their own careers. "We are a high- 
volume medical facility in part 
because of our advanced technol- 
ogy," he explains. "But our physi- 
cians and staff and the 
long-standing reputation of col- 
leagues such as Doctor Dacey are 
what continue to bring surgical 
and radiology referrals to Washing- 
ton University Medical Center. 
And, ultimately, that equates to 
lives saved." mm 
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Tracking Elusiue 
Prostate Cancer 
fl NEW STUDV HT MflLLINCKRODT 
INSTITUTE USES 11C-ACETATE AND 
PET TO DETERMINE TREATMENT FOR 
PATIENTS UJITH PROSTATE CANCEA. 
medicine on sophisticated computer 
applications such as reconstruction 
orithms and display techniques for 
hree-dimensional data, Tom Miller, pro- 
fessor of radiology and of 
biomedical engineering, 
had seen this young field 
cessing reach successful 
maturity, in part through his own pio- 
neering efforts. In 1997, he was ready 
for a neuj challenge that mould combine 
physics and nuclear medicine. But, ujhat 
should it be? 
by     Candace     O'Connor 
H Tracking Elusiue Prostate Cancer 
a I kind of stuck my head 
out of the door of my 
office and heard this 
swish-swish-swish 
sound," he says, moving 
his head from side-to-side. "PET, 
PET, PET [positron emission tomog- 
raphy]. PET tumor imaging, PET 
oncology. You hear 'PET' echoing 
up and down the halls of Mallinck- 
rodt Institute at a deafening pitch. 
It didn't take a genius to figure out 
what I was going to do." 
So Miller decided to re-tool his 
career and focus on tumor-imaging 
research with PET, a technology 
developed at Mallinckrodt Institute 
of Radiology (MIR) in the 1970s. 
Soon that new interest led Miller to a 
study of cervical cancer using PET and 
18F-FDG, a radiopharmaceutical effec- 
tive in tumor imaging. 
More recently, Miller's interest has 
resulted in two important studies of 
prostate cancer, the most commonly 
diagnosed cancer in men in the United 
States and the second-leading cause of 
cancer deaths in men over age 40. In a 
pilot study, now completed, Miller and 
a group of collaborators looked at the 
effectiveness of HC-acetate, another 
radiopharmaceutical used in PET imag- 
ing, to diagnose recurrent prostate can- 
cer. In a second study, still ongoing, 
investigators are testing whether PET 
and HC-acetate can reliably determine 
the full extent of cancer present in 
high-risk patients who were recently 
diagnosed with prostate cancer. 
Nuclear Medicine Physician Tom Miller earned a PhD degree in nuclear physics from Stanford University and an 
MD from the University of Missouri-Columbia. Prior to joining the MIR faculty in 1981, he completed a 
residency at the Institute. 
"Although prostate cancer is a 
major problem, we lack good imaging 
methods to detect the disease," says 
Miller. "That is what we are address- 
ing here: If we can find cancer metas- 
tasis that is missed by conventional 
imaging methods at the time of diag- 
nosis, that discovery could lead to a 
major alteration in treatment for these 
patients. So we will have a big payoff 
if this method works." 
Prostate cancer 
screening 
Diagnosing prostate cancer in its 
early stages used to be problem- 
atic—until William Catalona, 
MD, former head of the Division of 
Urologic Surgery at Washington 
University in St. Louis School of 
Medicine (WUSM), pioneered the 
prostate-specific antigen (PSA) test in 
the early 1990s. Widespread PSA 
screening has since led to the much 
earlier diagnosis of prostate cancer. 
Screening 
works this way: 
When a man's PSA 
level is elevated, 
prostate cancer may 
be present, and a 
biopsy is performed 
for confirmation. If 
that test is positive, 
the next step is to 
determine how the 
disease should be 
treated. Younger 
men with localized 
cancer often 
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undergo a radical prostatectomy; 
older men for whom surgery would 
be risky have primary treatment of 
radiation therapy. 
The situation becomes more 
complicated when the cancer has 
spread beyond the prostate gland. 
For these patients, surgery would no 
longer provide a cure; instead, they 
may need systemic hormone therapy. 
Thus, if physicians know the cancer 
has metastasized, patients can avoid 
a risky surgical procedure, which 
would provide no benefit and has 
associated adverse effects, or a long 
course of radiation therapy. 
However, it is sometimes diffi- 
cult to tell whether a newly diag- 
nosed patient has disease in the 
lymph nodes or in more distant sites. 
As part of the diagnostic exam, this 
patient should have a bone scan and 
an initial computed tomography (CT) 
scan to check if the disease has 
spread. Often, especially if the man's 
PSA level was relatively low, these 
tests show negative results; however, 
in some cases, these results may be 
misleading. 
PET's role in detecting 
hidden cancer 
I hile prostate cancer is gen- 
I erally a slow-growing dis- 
mJU ease, about 20 percent of 
patients—even those diagnosed 
through regular PSA testing—have a 
high-grade form of cancer with a 
more aggressive course. Recently, 
Mallinckrodt Institute physicians 
began providing radiologic services 
to the Veterans Administration (VA) 
Hospital in St. Louis. For reasons 
unclear at present, diagnostic testing 
is showing a higher-than-normal 
proportion of these veterans with 
high-grade prostate cancer. 
Such patients are 
more likely to have hidden 
disease at the time of diag- 
nosis, although their initial 
workup and tests show 
nothing suspicious. "It's 
difficult to find," says 
Miller. "We're studying 
whether the lymph nodes 
can be detected when the 
CT results are already 
negative, but we are limit- 
ing our study to cases in 
which PET imaging could 
really make a difference." 
PET is a potentially 
useful tool. Already, the 
combination of PET and 
18F-FDG has proven 
effective in detecting 
many other forms of can- 
cer, including lung, lym- 
phoma, colon, breast, melanoma, 
esophagus, liver, cervical, and recur- 
rent brain cancer. But FDG usually is 
not effective in detecting prostate 
cancer, probably because FDG is a 
sugar, an analog of glucose; prostate 
cancer has a low demand for energy 
since it grows so slowly. 
Finding a new, more effective 
radiopharmaceutical to use with 
PET was a key need. Miller's study 
of cervical cancer with FDG was 
underway when a preliminary 
abstract in a medical journal 
reported that HC-acetate PET 
seemed promising in detecting 
prostate cancer. 
Miller, who had worked on com- 
puter imaging with HC-acetate in 
measuring myocardial oxidative 
metabolism, was familiar with this 
agent. Better still, HC-acetate, 
which has an extremely short half-life 
of around 20 minutes, was already 
being produced in the Institute's 
radiological chemistry laboratory 
for use in cardiac studies. Further, 
the urologic surgery staff at 
Biopsy proven prostate recurrence 
following RT 
WA 
With 1 IC-acetate, lymph with tumor (n) 
and prostate recurrence (p) is clearly indicated. 
With FDG, result is negative for both tumor 
and recurrence. 





Barnes-Jewish Hospital could refer 
prostate cancer patients, as could the 
Department of Radiation Oncology's 
genitourinary service. 
Miller obtained two, successive 
pilot grants of $25,000 each from Site- 
man Cancer Center as well as a grant 
from the CaPCure Foundation to 
compare the effectiveness of 18F- 
FDG PET and HC-acetate PET in 
patients who had undergone radical 
prostatectomy or radiation therapy 
and subsequently developed a rising 
PSA level—indicating a likely disease 
recurrence. Some 30 percent of 
these men will have local recur- 
rences, while 70 percent will have 
distant disease with or without 
local recurrence. 
In comparative studies of 46 
patients using both radiopharmaceu- 
ticals—(30 men initially were treated 
with surgery; 16, with primary radia- 
tion)—investigators found that 
among those patients whose disease 
was confirmed by CT scan or biopsy, 
30 percent were identified by 11C- 
Pilot Grants Collaborators 
Nuclear Medicine 
Keith Fischer, MD 
Tom Miller, MD, PhD 
Barry Siegel, MD 
Jerald Andriole, MD 




acetate PET, while only 9 percent 
were identified by 18F-FDG PET. 
Clearly, HC-acetate PET was the 
much superior tool. 
Current Study 
Miller has now received 
National Institutes of Health 
(NTH) funding to continue 
investigating HC-acetate PET. Over 
a five-year period, the research team 
plans to accrue 200 to 300 newly 
diagnosed, high-risk patients who 
have a PSA level of 10 or greater, a 
Gleason (biopsy) score of at least 
seven, and bone and CT scans nega- 
tive for metastasis. Unlike patients 
whose initial PSA level is lower, men 
in this group are more likely to have 
cancer that has spread outside the 
prostate and has not shown up 
during the diagnostic workup. 
"Despite intensive PSA screen- 
ing, about ten percent to twenty 
percent of newly diagnosed cancer 
patients have advanced tumors," 
R lilelcome Rdditior 
PhD, 
a urologist on sabbatical from 
Japan's Fukui University, 
who was working in Welch's 
laboratory. (Oyama, who had 
worked with 11 C-acetate PET 
in Japan, not only .wrote a 
grant proposal that resulted in 
additional funding from the 
CaPCure Foundation but also 
was first author on a paper 
published in 2003 in the 
Journal of Nuclear Medicine.) 
says Gerald Andriole, MD, chief of 
WUSM's Division of Urologic 
Surgery. "There is an urgent need to 
identify these patients prior to treat- 
ment. Carbon eleven-acetate scan- 
ning may be useful for these patients, 
as well as for men with recurrence 
after surgery or radiation therapy. 
If we are able to more precisely 
stage such patients, we can optimize 
their treatments." 
Specifically, says Adam Kibel, 
MD, director of urologic oncology, 
"if we could identify those high-risk 
patients showing metastasis, they 
could be spared the morbidity of 
unnecessary surgery or radiation 
therapy. Also, high-risk patients 
whom we previously would not treat 
with curative intent now could be 
diagnosed as free of metastasis, and 
we could try to cure them." 
There should be no problem 
recruiting enough patients, since the 
surgeons and radiation oncologists at 
Washington University Medical 
Center annually treat approximately 
800 patients newly diagnosed with 
prostate cancer. The high-risk 
patients at the VA Hospital should 
provide another pool of patients, 
and the researchers also plan to 
contact some community urologists 
for referrals. 
So far, eight men with newly 
diagnosed prostate cancer have been 
tested, using the medical center's 
combined PET/CT scanner. Cary 
Siegel, MD, an associate professor of 
radiology with CT expertise, is inter- 
preting the patients' CT scans, while 
the study's nuclear medicine physi- 
cians are interpreting the PET scans. 
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Results to date have been 
encouraging. Among the study's 
eight patients, two men have shown 
evidence of cancer metastasis that 
was not apparent on the bone scan or 
on the CT scan. In one patient, the 
cancer had spread to a tiny lymph 
node near the prostate. The PET scan 
of the other patient showed affected 
lymph nodes in the abdomen and in 
the neck, with the neck node con- 
firmed by ultrasound-guided biopsy. 
"Unfortunately, this patient has 
documented metastatic cancer," says 
Jeff Michalski, MD, chief of Radiation 
Oncology's genitourinary service, 
"but because the metastasis was 
detected, he has avoided a long 
regimen of expensive, unnecessary 
radiation therapy that would not have 
provided any benefit. He is receiving 
hormone therapy, a dramatic change 
in his care." 
With many more patients to be 
enrolled in the study, Miller and his 
colleagues are cautiously optimistic 
about HC-acetate 
PET as an important 
prostate cancer tool. 
This radiopharma- 
ceutical does have 
some inherent limi- 
tations: primarily, a 
20-minute half-life 
that, unlike the 110- 
minute half-life of 
18F-FDG, limits its 
use to an institution 




has two in-house 
cyclotrons and was 
the first medical 
facility in the 
United States to have a dedicated 
cyclotron.] MTR's radiological chem- 
istry laboratory, headed by Michael 
Welch, PhD, is currently performing 
animal studies with a new radiophar- 
maceutical, 18F-Fluoroacetate, which 
has the advantages of 1 lC-acetate 
plus a nearly two-hour half-life. 
Will patients with a positive PET 
scan have a worse long-term out- 
come than those patients whose PET 
scan was negative? There is currentiy 
no definitive answer to this question. 
But patients who participated in 
Miller's study will have follow-up 
care over several years, and their 
information could help change 
prostate cancer treatment and patient 
outcome. "If the study goes well," 
says Miller, "PET with carbon eleven- 
acetate could become a routine 
clinical test for men with a high-risk, 
new diagnosis of prostate cancer." 
If this study's conclusions are as 
hoped for, adds Michalski, "we will 
be better able to tailor treatment to 
those patients who are likely to bene- 
fit from it, to avoid the morbidity and 
toxicity for patients who will not 
benefit from treatment, to avoid 
unnecessary surgeries if patients 
have evidence of metastasis, and to 
identify a group of patients who 
require therapy that is either more 
aggressive or more innovative than 
what we have been able to provide." 
Editor's Note: Urologists who wish 
to refer patients to the HC-acetate 
PET study or would like more infor- 
mation about the use of this test in 
the clinical setting may contact the 
study coordinators, Jennifer Frye 
and Helen Kaemmerer, at (314) 
362-7021. EH 
Jeff Michalski, MD, also serves as director of 
the Clinical Division in the Department of 
Radiation Oncology. 
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In this section, the names of employees who are full-time 
faculty or staff or who have an appointment in the 
Department of Radiology or Department of Radiation 
Oncology are highlighted in boldface type. 
NEW FACULTY 
Michael Penney, MD, 
instructor in radiology, 
Division of Diagnostic Radi- 
ology (at Barnes Jewish 
St. Peters Hospital), Depart- 
ment of Radiology. 
Robert Steiner, MD, 
instructor in professor, 
Division of Diagnostic Radi- 
ology (at Barnes-Jewish 
St. Peters Hospital), Depart- 
ment of Radiology. 
GRANTS  
Samuel Achilefu, PhD, 
associate professor of radiol- 
ogy, as principal investiga- 
tor, received a $153,000 
grant from the National 
Institutes of Health for 
research on "Novel 
monomolecular multimodal- 
ity imaging agents. Coinves- 
tigators for the one-year 
award are Michael, Welch, 
PhD, professor of radiology, 
of chemistry, and of molecu- 
lar biology and pharmacol- 
ogy; Barry Siegel, MD, 
professor of radiology and 
ofg medicine; Gregory Lanza, 
MD, assistant professor of 
medicine; Samuel Wickline, 
MD, professor of medicine; 
and Brinton Chance, MD, 
University of Pennsylvania. 
Kevin Black, MD, assistant 
professor, of psychiatry, of 
neurology, and of radiology, 
as site principal investigator, 
received a grant from the 
National Institute of Neuro- 
logical Disorders for 
research on "Serotonergic 
antidepressant in Parkin- 
son's disease." As site 
principal investigator, he 
also received a one-year 
grant from ACADIA Pharma- 
ceuticals for "Phase 2, 
multi-center, placebo con- 
trolled, double blind trial of 
ACP-103 in the treatment 
of psychosis in Parkinson's 
disease (Clinical protocol # 
ACP-103-006)." 
Thomas Conturo, MD, 
PhD, associate professor 
of radiology and adjunct 
professor of physics and 
biomedical engineering, as 
principal investigator, 
received a one-year grant of 
$56,390 from Sun Microsys- 
tems, Inc. for research on 
"Computational hardware 
for MRI research and devel- 
opment." As principal inves- 
tigator, he also received a 
one-year grant of $8,000 
from Mallinckrodt, Inc/Tyco 
Healthcare, Inc. to study 
"MRI compatibility of patient 
accessories in phantoms and 
animals." 
Robert Gropler, MD, 
professor of radiology, of 
medicine, and of biomedical 
engineering, as principal 
investigator, received a 
$3.7 million grant from the 
National Institutes of Health, 
for research on "Altered 
myocardial fatty acid metab- 
olism in obesity." Coinvesti- 
gators for the five-year 
award are Pilar Herrero, MS, 
research scientist in radiol- 
ogy; Samuel Klein, MD, 
professor of medicine; and 
Linda Peterson, MD, assis- 
tant professor of medicine. 
Joel Perlmutter, MD, 
professor of neurology, 
of neurological surgery, of 
radiology, and of physical 
therapy, as principal investi- 
gator, received a $1.9 million 
grant from the National Insti- 
tutes of Health (NIH) and a 
$25,000 fellowship grant 
from Medtronic, Inc. for 
research on "Mechanisms 
of deep brain stimulation." 
Theodore Cicero, PhD, vice 
chancellor for research, as 
principal investigator, and 
Perlmutter, as co-principal 
investigator, received a $1.8 
million award from NIH for 
renovations needed to com- 
plete a 14,000 square feet, 
neuroclinical research unit. 
Joshua Shimony, MD, 
PhD, assistant professor of 
radiology, as principal inves- 
tigator, received a two-year 
grant of $80,000 from the 
McDonnell Center for the 
Studies of Higher Brain 
Function for research on 
."Mapping neuronal connec- 
tivity in the human visual 
cortex and in the frontal- 
parietal region." 
Marilyn Siegel, MD, pro- 
fessor of radiology and of 
pediatrics, received a one- 
year grant of $5,000 from 
the Society for Pediatric 
Radiology for research on 
"Measurements of epicardial 
and visceral fat: correlation 
with treatment options." 
APPOINTMENTS/ 
ELECTIONS 
Carolyn Anderson, PhD, 
associate professor of radiol- 
ogy, was elected to a two- 
year term as secretary/ 
treasurer of the Society 
for Radiopharmaceutical 
Chemistry and Biology. 
Colin Derdeyn, MD, 
associate professor of 
radiology, was appointed as 
a consultant to the Neurolog- 
ical Devices Panel of the 
Medical Devices Advisory 
Committee for the Food 
and Drug Administration's 
Center for Devices and 
Radiological Health. 
Jay Heiken, MD, professor 
of radiology, was appointed 
to a one-year term on the 
American College of Radiol- 
ogy Imaging Network 
Gastrointestinal Disease 
Site Committee. 
Susan Langhorst, PhD, 
CHP, assistant professor of 
radiology, was appointed to 
a two-year term as a member 
of the National Academies of 
Science Board on Radioac- 
tive Waste Management. 
Linda Larson-Prior, PhD, 
research associate professor 
of radiology, was elected 
treasurer of the Executive 
Board of the Organization 
for Computational Neuro- 
science. 
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obert McKinstry, MD, 
hD, assistant professor of 
adiology, was appointed to 
seven-year term as chair- 
lan of the Neuroradiology 
ommittee and as a member 
f the Executive Committee 
if the Silent Cerebral Infarct 
vlulticenter Trial, funded by 
ihe National Institute of 
Neurological Disorders. 
He was appointed codirector 
of the Mallinckrodt Institute 
Research Residency Training 
Program. 
Eduardo Moros, PhD, 
associate professor of radia- 
tion oncology, was elected to 
a four-year term as president 
of the International Associa- 
tion for Hyperthermic 
Oncology, the international 
organization representing 
the North American Hyper- 
thermia Society (NAHS), 
the European Society for 
Hyperthermic Oncology, 
and the Asian Society for 
Hyperthermic Oncology. 
He also was elected to a one- 
year term (2004-2005) as 
president of NAHS. 
Bradley Schlaggar, MD, 
PhD, assistant professor 
of neurology, of radiology, 
of pediatrics, and of anatomy 
and neurobiology, was 
appointed consulting editor 
for the journal Develop- 
mental Psychology. 
Biello Lecture MIL.,. 
Former MIR faculty mem- 
ber, Landis Griffeth, MD, \ 
PhD, presented the Eigh- 
teenth Annual Daniel R. 
Biello Memorial Lecture on ^^AH        H ^^^^^fljl                $^ 
March 8. Griffeth, director 
of nuclear medicine in the iKifift tV 
Department of Radiology at 
Baylor University Medical LJI^LI 
Center (Texas), presented 
"Lymphoma: a model 
for PET's role hi cancer 
management."                                ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ 
Griffeth (left) is shown with Barry Siegel, MD chief, Division of Nuclear Medicine, and coordinator of the 
Biello Lecture. 
Barry Siegel, MD, profes- 
sor of radiology and of 
medicine, was elected to a 
three-year term as a mem- 
ber-at-large of the Academy 
of Molecular Imaging Board 
of Directors. 
Marilyn Siegel, MD, pro- 
fessor of radiology and of 
pediatrics, was appointed 
as a consultant to the Food 
and Drug Administration 
for pediatric cardiac and 
extracardiac vascular 
imaging using computed 
tomography and magnetic 
resonance angiography. 
Bruce Whiting, PhD, 
research professor of radiol- 
ogy, was elected as the 2004 
chairman of the St. Louis 
Chapter of the Engineering 
in Medicine and Biology 
Society of the Institute of 
Electrical and Electronics 
Engineers. 
Pamela Woodard, MD, 
assistant professor of 
radiology, was elected to a 
two-year term as secretary- 
treasurer of the North 




Thomas Conturo, MD, 
PhD, associate professor 
of radiology and adjunct pro- 
fessor of physics and bio- 
medical engineering, was 
invited to serve as guest 
editor of the Journal of 
Magnetic Resonance Imag- 
ing's special issue on 
"Quantitative cerebral 
perfusion imaging using MRI: 
a technical perspective." 
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Robert Malyapa, MD, PhD, 
assistant professor of radia- 
tion oncology, received the 
Radiation Therapy Oncology 
Group's (RTOG's) Simon 
Kramer New Investigator 
Award for his research pro- 
ject "Oncologic imaging of 
tumor hypoxia and correlat- 
ing findings on Cu-ATSM 
PET scans to cellular mark- 
ers that may predict for radi- 
ation response." The award 
was presented in January at 
the RTOG Winter Semi- 
Annual Meeting in New 
Orleans, Louisiana. 
Stephen Moerlein, PhD, 
associate professor of radiol- 
ogy and of biological chem- 
istry, and Yuan-Chuan Tai, 
PhD, assistant professor of 
radiology, received the 
Image of the Year Award for 
their research on "Quantita- 
tive neuroreceptor imaging 
of transgenic mice" at the 
Concorde Microsystems Inc. 
Users Meeting in March. 
Douglas Rowland, PhD, 
research instructor of radiol- 
ogy, received the Best Dra- 
matic Dynamic Image of the 
Year Award at the Concorde 
Microsystems Inc. Users 
Meeting in March. Row- 
land; Richard Laforest, 
PhD, assistant professor of 
radiology; Yaun-Chuan Tai, 
PhD, assistant professor of 
radiology; and Michael 
Welch, PhD, professor of 
radiology, of chemistry, and 
of molecular biology and 
pharmacology, used the 
microPET scanner to pro- 
duce the award-winning 
gated cardiac images. 
LECTURES 
Carolyn Anderson, PhD, 
associate professor of radiol- 
ogy, presented "Copper-64- 
labeled biomolecules for 
tumor targeting" at 
Lawrence Berkeley Labora- 
tory, Berkeley, California, 
January 28. 
Sanjeev Bhalla, MD, assis- 
tant professor of radiology, 
as invited speaker, presented 
"Finding blue pearls: Eastern 
reflections on Western medi- 
cine" at the 51sl Annual Alpha 
Omega Alpha Lecture, 
Washington University in 
St. Louis, Missouri, April 6. 
Kevin Black, MD, assistant 
professor of psychiatry, of 
neurology, and of radiology, 
spoke on "Neuroimaging 
studies of dopaminergic 
function in Tourette Syn- 
drome" at the Tourette Syn- 
drome Association Young 
Investigators Symposium, 
Atlanta, Georgia, January 31. 
Jeffrey Bradley, MD, assis- 
tant professor of radiation 
oncology, presented "Dose 
response and complications" 
at the Optimizing of Thoracic 
Irradiation: RTOG Sympo- 
sium, sponsored by the Radi- 
ation Therapy Oncology 
Group, New Orleans, 
Louisiana, January 16. He 
spoke on "Current issues in 
conformal radiotherapy for 
lung cancer: targeting 
tumors with FDG-PET" at 
the National Institutes of 
Health/National Cancer Insti- 
tute, Bethesda, Maryland, 
March 31 and April 1. He pre- 
sented "Radiation treatment 
planning with PET/CT" at 
the CMS Users Meeting, St. 
Louis, Missouri, April 25. 
Jeffrey Brown, MD, associ- 
ate professor of radiology, 
presented "Diagnosis and 
staging of cholangiocarci- 
noma and gallbladder 
cancer by MRI" at the 12th 
Annual WUSM Refresher 
Course and Update in Gen- 
eral Surgery, St. Louis, Mis- 
souri, February 26. 
Thomas Conturo, MD, 
PhD, associate professor of 
radiology and adjunct pro- 
fessor of physics and bio- 
medical engineering, spoke 
on "Research and develop- 
ment of dynamic susceptibil- 
ity contrast perfusion MRI 
for neurological studies" and 
"Beyond the tensor: mea- 
surement of displacement 
probabilities and other diffu- 
sion parameters in tissues" 
at the Symposium on 
Advanced Magnetic Reso- 
nance Imaging in Neuro- 
science, Istituto Nazionale 
•Neurologico "Carlo Besta," 
Milan, Italy, March 24. 
Maurizio Corbetta, MD, 
associate professor of neu- 
rology and of radiology, pre- 
sented "The attention system 
of the human brain" to the 
Department of Neuro- 
science, Medical College of 
Wisconsin, Milwaukee, Janu- 
ary 21. He spoke on "A strat- 
egy to investigate recovery 
of cognitive functions with 
functional brain imaging" at 
the International Symposium 
on Neuroimaging of Stroke 
Recovery, Columbia Univer- 
sity, New York City, New 
York, February 2 and 3. He 
spoke on "Brain systems for 
the control of perception 
and action" at the Neuro- 
science Colloquium, spon- 
sored by the French National 
Center for Scientific 
Research (CNRS), Lyons, 
France, February 6. Corbetta 
presented "From neurology 
to neuroscience: brain imag- 
ing studies of visual atten- 
tion in the normal and 
damaged brain" at Brain Sci- 
ences Lectures, University of 
Chieti, Italy, February 10. He 
presented "Stroke recovery: 
a neuroimaging approach" at 
the Clinical Neuroscience 
Grand Round, Fatebene- 
fratelli Hospital, Rome, Italy. 
February 12. Corbetta spoke 
on "Brain imaging studies of 
neurological recovery in 
brain and spinal cord injury 
at the Clinical Neurosciencr 
Grand Round, Southwesten 
Medical University, Dallas, 
Texas, March 3. He pre- 
sented "The influence of 
action on visual cortex" at 
the International Conference 
on New Perspective in 
Vision, Isle of Mull, Scotlan , 
April 14-16. 
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,olin Derdeyn, MD, asso- 
iate professor of radiology, 
iresented "Role of cerebral 
lemodynamics in ischemic 
troke" and "Treatment of 
arotid atherosclerotic dis- 
ease: medicine, surgery, or 
tent" at the Colorado Radio- 
ogical Society meeting, Den- 
ver, January 15. He spoke on 
A patient with complete 
carotid occlusion" at the 
St. Louis Vascular Surgery 
29* Annual Meeting, 
St. Louis, Missouri, January 
19. Derdeyn spoke on 
"Management of posterior 
circulation aneurysms" and 
"Selection of patients for 
cerebral revascularization: 
the role of hemodynamic 
assessment" at the 7th Annual 
Joint Meeting of the Ameri- 
can Association of Neurolog- 
ical Surgeons/Congress of 
Neurological Surgeons Joint 
Section on Cerebrovascular 
Disease and the American 
Society of Interventional and 
Therapeutic Neuroradiology, 
San Diego, California, Febru- 
ary 2 and 3. He presented 
"The carotid occlusion 
surgery study" at Medical 
Grand Rounds, Alton Memo- 
rial Hospital, Alton, Illinois, 
February 18. 
Cardiovascular MR Course 
Twenty participants attended the 6th annual "Cardio- 
vascular MR Course: Hands-on Experience," held in 
the Institute's East Building on January 20-22. Course 
faculty: Pamela Woodard, MD, course director; 
Glenn Foster, RT; Robert Gropler, MD; Fernando 
Gutierrez, MD; Richard Nagel, RT; Vamsidhar 
Narra, MD; Orlando Simonetti, PhD (Northwestern 
University); and Gary McNeal (Northwestern Univer- 
sity and Siemens Medical Systems). 
For more information about this course, call (314) 
747-3878. 
Steven Don, MD, associate 
professor of radiology, 
spoke on "Radiosensitivity 
of children: potential for 
overexposure in CR and 
DR and magnitude of doses 
in ordinary radiographic 
examinations" at the ALARA 
Concept in Pediatric CR 
and DR, Houston, Texas, 
February 28. 
Louis Gilula, MD, profes- 
sor of radiology, of 
orthopaedic surgery, and 
of plastic and reconstructive 
surgery, presented "Verte- 
broplasty in fractures with 
spinal cord impingement" 
at the Society of Skeletal 
Radiology, Tucson, Arizona, 
March 9. As visiting profes- 
sor, he spoke on "Cervical 
spine trauma" at the Oregon 
Health and Science Univer- 
sity, Portland, April 15. 
Perry Grigsby, MD, profes- 
sor of radiation oncology 
and of radiology, spoke on 
"Radiation therapy for can- 
cer of the thyroid," "Multi- 
modality management of 
cancer of the cervix," and 
"Treatment of endometrial 
cancer" at the 56th Annual 
Midwinter Radiation Oncol- 
ogy Conference, Los Ange- 
les, California, January 
23-25. He presented "New 
imaging techniques" at the 
35th Annual Meeting of the 
Society of Gynecologic 
Oncologists, San Diego, 
California, February 9-11. 
Jay Heiken, MD, professor 
of radiology, presented "CT 
colonography: technique, 
results and future direc- 
tions"; "MDCT evaluation of 
small bowel obstruction"; 
"Characterization of hepatic 
masses with helical CT"; and 
"CT of the abdominal aorta: 
aneurysm rupture and post- 
operative complications" at 
Computed Body Tomogra- 
phy 2004: the Cutting Edge, 
sponsored by Johns Hopkins 
University, Orlando, Florida, 
February 12-15. He moder- 
ated a session on "Imaging of 
acute abdominal conditions" 
and spoke on "Imaging small 
bowel obstruction" at ARC 
2004 Abdominal Radiology, 
presented by the Society of 
Gastrointestinal Radiologists 
and the Society of Uroradiol- 
ogy, Scottsdale, Arizona, 
March 7-12. He spoke on 
"Contrast medium adminis- 
tration and scan timing for 
MDCT" and "Aortic stent 
grafts: pre-operative and 
post-operative evaluation 
with MDCT" at New 
Advances in Non-Invasive 
Vascular Imaging 2004, 
San Francisco, California, 
April 3. 
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LECTURES 
Continued from page 27 
Charles Hildebolt, DDS, 
PhD, associate professor of 
radiology and adjunct associ- 
ate professor of anthropol- 
ogy, spoke on "Effect of 
vitamin D and calcium on 
periodontitis," "Tips on writ- 
ing grant proposals," and 
"The new clinical trials 
program at the National 
Institutes of Dental and 
Craniofacial Research" at the 
Southern Illinois University 
School of Dental Medicine, 
Alton, Illinois, April 27. 
Purdy Lecture 
Thomas Mackie, PhD, professor of medical physics, 
human oncology, and of engineering physics at the 
University of Wisconsin, Madison, was guest 
speaker for the Second Annual James A. Purdy 
Medical Physics Lecture on April 30. Mackie spoke 
on "Tomotherapy and beyond." 
(Left to right) Marilyn Purdy; James Purdy, PhD; Mackie; and Todd 
Wasserman, MD. 
Richard Laforest, PhD, 
assistant professor of radiol- 
ogy, presented "Recent 
advances in microPET imag- 
ing of rodents" at the Site- 
man Cancer Center 
Oncologic Imaging Retreat, 
St. Louis, Missouri, March 
13. He presented "An intro- 
duction to the microPET- 
FOCUS120"atthe 
microPET Users meeting, 
Orlando, Florida, March 27. 
He spoke on "Requirements 
for quantitative PET imag- 
ing" at the National Cancer 
Institute Advanced Technol- 
ogy Symposium, April 14. 
Wayne Lamoreaux, MD, 
radiation oncology chief resi- 
dent, presented "FDG-PET 
evaluation in patients with 
carcinoma of the vagina" at 
the 26th International Sympo- 
sium on Radioactive Iso- 
topes in Clinical Medicine 
and Research, Bad Gastein, 
Austria, January 13-16. 
Jason Lewis, PhD, assis- 
tant professor of radiology, 
spoke on "Non-invasive mea- 
surement of hypoxia by 
imaging—Cu-ATSM" at 
Hypoxia: Importance in 
Tumor Biology, Non-Invasive 
Measurement by Imaging, 
and Value of its Measure- 
ment in the Management of 
Cancer Therapy, sponsored 
by the National Cancer 
Institute, Phoenix, Arizona, 
April 7. 
Jacob Locke, MD, assistant 
professor of radiation oncol- 
ogy, presented "Enhance- 
ment of hyperthermic 
radiosensitization with 
Celecoxib: molecular tar- 
gets" at the 95th Annual 
Meeting of the American 
Association for Cancer 
Research, Orlando, Florida, 
March 27-31. He presented 
"Celecoxib enhances hyper- 
thermic radiosensitization" 
at the 93rd Annual Meeting of 
the American Association for 
Cancer Research—Radiobi- 
ology, Laguna, California, 
April 6-10. 
Stephen Moerlein, PhD, 
associate professor of radiol- 
ogy and of biological chem- 
istry, spoke on "Preparation 
of[C-ll]lS-CFTforPET 
measurement of dopamine 
transport activity" at the 
2004 Annual Meeting of the 
American Pharmacists Asso- 
ciation, Seattle, Washington, 
March 26-30. 
Eduardo Moros, PhD, 
associate professor of radia- 
tion oncology, presented 
"The development of sys- 
tems to expose cells and 
animals to electromagnetic 
radiation. Engineering expe- 
rience and summary to bio- 
logical results" at the Joint 
Graduate Program in Bio- 
medical Engineering Spring 
2004 Seminar Series, spon- 
sored by the University of 
Memphis and the Universit. 
of Tennessee Health Sciem ' 
Center, Memphis Tennesse 
March 12. 
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"ej Pandita, PhD, assistant 
professor of radiation oncol- 
■gy, spoke on "Mammalian 
rthologue of Drosphilia 
[AT influences ATM func- 
;on and embryonic develop- 
ment" at the EMBO 
/orkshop/SS"1 Harden Con- 
erence—Telomeres and 
lenome Stability, sponsored 
by The Biochemical Society, 
London, England, April 3-7. 
Carlos Perez, MD, profes- 
sor of radiation oncology, 
presented "Chemoirradiation 
in locally advanced carci- 
noma of the uterine cervix" 
and "Radiation therapy in 
the treatment of carcinoma 
of the uterine cervix" at 
Memorial Regional Hospital, 
Hollywood, Florida, Febru- 
ary 7. He presented "Prog- 
nostic factors in early breast 
cancer," "Management of 
carcinoma of the rectum," 
and "Chemoirradiation for 
locally advanced carcinoma 
of the uterine cervix" at XXI 
Renunon Nacional Medica 
del Instituto, Veracruz, Mex- 
ico, February 10-14. He 
spoke on "Radiopharmaceu- 
ticals in bone metastases" at 
the St. Louis Society of 
Medical Oncology, St. Louis, 
Missouri, February 17. 
Joel Perlmutter, MD, 
professor of neurology, of 
neurological surgery, of radi- 
ology, and of physical ther- 
apy, spoke on "Parkinson's 
disease: new pathophysio- 
logical investigations" at 
Neuroscience Grand 
Rounds, St. John's Mercy 
Medical Center, St. Louis, 
Missouri, February 18. He 
presented "PET investiga- 
tions of movement disor- 
ders" at the 2004 Annual 
Meeting of the Academy of 
Molecular Imaging, Orlando, 
Florida, March 27-31. 
Joseph Roti Roti, PhD, 
professor of radiation oncol- 
ogy, presented "Heat shock 
effects on the DNA repair 
protein MRE11 and radiosen- 
sitization by clinically rele- 
vant thermal doses" and 
"Lack of biological effects 
from some electromagnetic 
radiations (i.e., cellular tele- 
phones) but not from others" 
at Experimental Radiation 
Oncology, sponsored by 
The University of Texas 
M.D. Anderson Cancer 
Center, Houston, Texas, 
February 12. 
Douglas Rowland, PhD, 
research instructor of radiol- 
ogy, spoke on "Respiratory 
and cardiac gating: R4 and 
focus" at the Concorde 
Microsystems Inc. Users 
Meeting, Orlando, Florida, 
March 26. 
Bradley Schlaggar, MD, 
PhD, assistant professor of 
neurology, of radiology, of 
pediatrics, and of anatomy 
and neurobiology, presented 
"The developmental func- 
tional neuroanatomy of lexi- 
cal processing" at the Mental 
Retardation/Developmental 
Disabilities Research Center, 
Kennedy Krieger Institute, 
Baltimore, Maryland, Febru- 
ary 2, and at the Vanderbilt 
University Institute of 
Imaging Science Seminar, 
Memphis, Tennessee, 
February 19. 
Barry Siegel, MD, profes- 
sor of radiology and of medi- 
cine, presented "Clinical 
applications of PET in oncol- 
ogy" at a meeting sponsored 
by Clinical Multi-Imaging 
PET-CT, Rio de Janeiro, 
Brazil, January 24. He pre- 
sented "Overview of PET in 
oncology," "PET and lung 
cancer," "Assessing response 
to therapy with PET," and 
"Oncologic PET: beyond 
FDG" at the 4th Annual Snow- 
bird 2004 Meeting, Clinical 
Nuclear Medicine: Focus on 
PET and PET/CT, Snowbird, 
Utah, March 21-26. He spoke 
on "PET artifacts/variants," 
"Pulmonary nodule and lung 
cancer," and "PET in 
women's imaging" at Clinical 
Nuclear Medicine, sponsored 
by Harvard Medical School, 
Boston, Massachusetts, 
April 27-30. 
Marilyn Siegel, MD, pro- 
fessor of radiology and of 
pediatrics, spoke on "Pedi- 
atric CT angiography," "CT 
angiography of adult medi- 
astinal vascular anomalies," 
and "Non-coronary cardiac 
CT" at the Advanced Topics 
in CT Scanning: CT Angiog- 
raphy, 3D Imaging, Virtual 
Imaging Course, sponsored 
by Johns Hopkins University, 
Los Angeles, California, 
March 26-28, and in Balti- 
more, Maryland, April 2-4. 
Franz Wippold, MD, asso- 
ciate professor of radiology, 
presented "Imaging of the 
herniated lumbar disk" to 
the American Academy of 
Orthopaedic Surgeons, 
San Francisco, California, 
March 10. 
SYMPOSIA 
In this section ofFYI, only 
those faculty and staff 
who have Department of 
Radiology or Department 
of Radiation Oncology 
appointments are listed. 
AMERICAN COLLEGE OF 
CARDIOLOGY 
53"' Annual Scientific 
Session Eocposition 
New Orleans, Louisiana 
March 7-9, 2004 
Pilar Herrero, MS, 
cochair, Positron Emission 
Tomography: Clinical 
Studies. 
FOCAL SPOT, SPRING 2004 29 
SYMPOSIA 
Continued from page 29 
POSTER PRESENTATIONS 
Pilar Herrero, MS; Joon- 
young Kim, PhD; Terry 
Sharp; Carmen Dence, 
MS; Jason Lewis, PhD; 
Robert Gropler, MD; 
Michael Welch, PhD, 
"Assessment of myocardial 
perfusion and metabolism in 
normal and diabetic rats by 
microPET imaging." 
Cheng Hong, MD; Pamela 
Woodard, MD; Kyongtae 
Bae, MD, PhD, "Assessment 
of coronary artery stent 
patency with in-stent con- 
trast enhancement in multi- 
row detector computed 
tomography angiography." 
ORAL PRESENTATIONS 
Robert Gropler, MD, "Non 
invasive imaging in the dia- 
betic population: nuclear 
cardiology, electron beam 
computed tomography"; 
"Patients with the metabolic 
syndrome have a high preva- 
lence of left ventricular dias- 
tolic dysfunction." 
Pilar Herrero, MS; Zulila 
Kisrieva-Ware, MD, PhD; 
Carmen Dence, MS; 
Robert Gropler, MD, 
"Impact of increased fatty 
acid delivery on myocardial 
fatty acid metabolism in 
obese young women." 
INTERNATIONAL SOCIETY 
FOR MAGNETIC RESO- 
NANCE IN MEDICINE 
Workshop on Quantitative 
Cerebral Perfusion Imaging 
with MRI: A Technical 
Perspective 
Venice, Italy 
March 21-23, 2004 
Thomas Conturo, MD, 
PhD, Workshop organizer; 
session moderator, 
"Dynamic susceptibility con- 
trast MRI theory." 
ORAL PRESENTATIONS 
Erbil Akbudak, PhD; 
Melanie Kotys; Dunja 
Memisevic; Thomas Con- 
turo, MD, PhD, "Quadratic- 
ity and hematocrit 
dependence of Delta R2* AIF 
signals at 3T: a blood phan- 
tom study under physiologic 
conditions." 
Erbil Akbudak, PhD; 
Melanie Kotys; Thomas 
Conturo, MD, PhD, "A dual 
sensitivity interleaved DSC 
EPI sequence for imaging 
brain perfusion with AIF 
sampling." 
Thomas Conturo, MD, 
PhD; Erbil Akbudak, PhD; 
Melanie Kotys; Joanne 
Markham, MS, "Arterial 
input functions for dynamic 
susceptibility contrast MRI: 
requirements and signal 
options." 
Melanie Kotys; Erbil 
Akbudak, PhD; Thomas 
Conturo, MD, PhD, "Opti- 
mal dose determination for 
Delta R2* and Delta phi 
arterial input functions 
using simulations." 
POSTER PRESENTATIONS 
Melanie Kotys; Erbil 
Akbudak, PhD; Thomas 
Conturo, MD, PhD, Effect 
of signal-to-noise ratio on 
signal saturation and dose 
dynamic range in bolus 
gadolinium Delta R2* and 
Delta phi arterial input 
functions." 
Dunja Memisevic; Melanie 
Kotys; Erbil Akbudak, 
PhD; Thomas Conturo, 
MD, PhD, "A blood AIF 
phantom with physiologic 
pulsatility, velocity, oxygena- 
tion and temperature for 
gated-MRI bolus-Gd studies." 
SOCIETY OF COMPUTED 
BODY TOMOGRAPHY 
AND MAGNETIC RESO- 
NANCE 
27th Annual Course 
Henderson, Nevada 
March 22-26, 2004 
CUM LAUDE RESEARCH 
ABSTRACT AWARDS 
Kyongtae Bae, MD, PhD; 
Cheng Hong, MD; Srini- 
vasa Prasad, MD; Mark 
Nolte; Paul Eisenbeis; Jay 
Heiken, MD, "Carbon diox- 
ide enhanced CT imaging for 
the detection of pulmonary 
emboli: feasibility study in a 
porcine model." 
Kyongtae Bae, MD, PhD; 
Srinivasa Prasad, MD; Jay 
Heiken, MD, "CT character- 
ization of adrenal masses 
using histogram analysis 
method." 
WORKSHOPS 
Kyongtae Bae, MD, PhD, 
"Principles/X-ray dose: 
CT/PET: basic principles." 
Jay Heiken, MD, "Endolu 
minal stent graft repair of 
abdominal aortic aneurysms: 
evaluation with MDCT." 
Stuart Sagel, MD, "CT 
angiography for pulmonary 
embolism"; Interactive tho- 
racic CT case discussions"; 
"Anatomic variants, 
anomalies and pitfalls in 
thoracic CT." 
Marilyn Siegel, MD, 
"Imaging common pediatric 
abdominal masses." 
Barry Siegel, MD, "PET in 
women's cancers." 
PRESENTATIONS 
Kyongtae Bae, MD, PhD; 
Victoria Chen; Jie Zheng, 
PhD; Charles Hildebolt, 
DDS, PhD; Premsri Bar- 
ton, MD, "Dynamic MR 
contrast enhancement 
characteristics of breast 
cancer: effect of contrast 
injection rate." 
_ 
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ongtae Bae, MD, PhD; 
leng Hong, MD, "Deter- 
ning optimal scan delay in 
-MDCT angiography." 
] ongtae Bae, MD, PhD; 
i ta Mody; Dennis Balfe, 
1 3; Sanjeev Bhalla, MD; 
1   vid Gierada, MD; Fer- 
li ando Gutierrez, MD; 
Christine Menias, MD; 
] imela Woodard, MD; Jin- 
Mo Goo, MD, PhD; 
Charles Hildebolt, DDS, 
I PhD, "Display window set- 
tings for depiction of pul- 
| monary emboli in CT: trends 
and variations among 
i observers." 
Jay Heiken, MD, "Imaging 
of small bowel obstruction 
I with MDCT." 
Marilyn Siegel, MD, 
"MR/CT of pediatric renal 
tumors," "CT of adrenal 
tumors." 
SOCIETY OF INTERVEN- 
TION RADIOLOGY 
29th Annual Meeting 
Phoenix, Arizona 
March 25-30, 2004 
Daniel Brown, MD, coordi- 
nator and moderator, Cate- 
gorical Course: Enteric 
Access: Percutaneous vs. 
Endoscopic—Which Would 
You Want? 
Wael Saad, MD, recipient, 
Travel Award. 
Suresh Vedantham, MD, 
panelist, Categorical Course: 
Lessons Learned—Venous 
Insufficiency. 
Thomas Vesely, MD, coor- 
dinator, Workshop: Venous 
Access; commentator, 
Central Venous Scientific 
Session. 
CATEGORICAL COURSES 
Daniel Brown, MD, "An 
enterostomy practice is good 
for your patients and you: 
how to target referrals and 
avoid trouble." 
Michael Darcy, MD, "Pal 
liative interventions for 
symptomatic fluid collec- 
tions." 
PLENARY SESSIONS 
Michael Darcy, MD, 
"Ambulatory phlebectomy: 
tips and techniques." 
Suresh Vedantham, MD, 
"Tumescent anesthesia: tips 
and techniques." 
Thomas Vesely, MD, 
"Vascular access surveil- 
lance: go with the flow"; 




MD; Thomas Pilgram, 
PhD; Daniel Brown, MD, 
"Power injection of micro- 
catheters: an in vitro com- 
parison." 
Wael Saad, MD; Michael 
Darcy, MD, "Stent-grafts in 
primary TIPS and in TIPS 
revisions: a single center 
experience." 
Wael Saad, MD, "Hepatic 
artery PTA after liver trans- 
plantation: the fatal kink"; 
"The natural history of 
hepatic artery stenosis in 
liver transplant recipients"; 
"Transhepatic dilation of 
anastomotic biliary stric- 
tures in liver transplants: sig- 
nificance of a patent hepatic 
artery"; "Safety and efficacy 
of fluoroscopic versus ultra- 
sound guided core liver biop- 
sies in live liver transplant 
donors." 
Thomas Vesely, MD, "Use 
of the peripheral cutting bal- 
loon to treat hemodialysis- 
related stenoses." 
POSTER PRESENTATIONS 
Wael Saad, MD, "Microbial 
contamination of bile follow- 
ing liver transplantations: de 
novo PTC versus indwelling 
biliary drains." 
WORKSHOPS 
Daniel Brown, MD, "Gas- 
trointestinal IR: techniques 
and management." 
Thomas Vesely, MD, 
"Hemodialysis access." 
INTERNATIONAL 
CONGRESS OF HYPER- 
THERMIC ONCOLOGY 
&'• Scientific Meeting 
St. Louis, Missouri 
April 20-24, 2004 
Katherine Bles, coordina- 
tor liaison, Local Arrange- 
ments Committee. 
Andrei Laszlo, PhD, mem- 
ber, Local Arrangements 
Committee. 
Jacob Locke, MD, cochair- 
man, Workshop: Whole Body 
Hyperthermia Modulation of 
Therapeutic Responses. 
Eduardo Moros, PhD, 
chairman, Local Arrange- 
ments Committee; chairman, 
Robinson Award Lecture; 
member, Organizing Com- 
mittee; coordinator, Scien- 
tific Program Committee; 
cochairman, Non-invasive 
Thermometry/Imaging Spe- 
cial Lectures Session. 
Robert Myerson, MD, 
PhD, cochairman, Plenary 
Symposium: New Random- 
ized Phase III Trials; mem- 
ber, Local Arrangements 
Committee. 
Joseph Roti Roti, PhD, 
chairman, Organizing Com- 
mittee; chairman, Plenary 
Lecture: Advances in PET 
Imaging of Hypoxia; mem- 
ber, Local Arrangements 
Committee. 
William Straube, MS, 
cochairman, Special 
Lecture: Advances in 
Hyperthermia/Thermal 
Therapy Devices. 
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WORKSHOPS 
Eduardo Moros, PhD, 
"Clinical SURLAS for super- 
ficial simultaneous ther- 
moradiotherapy." 
Robert Myerson, MD, 
PhD, "Monitoring the effect 
of41°C hyperthermia on 
tumor hypoxia by Cu-ATSM 
PET scanning." 
Robert VanderWaal, PhD, 
"Heat-shock induced overlap 
of euchromatin and hete- 
rochromatin DNA replica- 
tion." 
ORAL PRESENTATIONS 
Jacob Locke, MD, "Differ- 
ences in response to local- 
ized ultrasound versus 
waterbath hyperthermia: 
clinical implications." 
Tej Pandita, PhD, 
"Genomic instability and 
enhanced radiosensitivity in 
Hsp70.1/3-deficient mice." 
Michael Welch, PhD, 
"Advances in PET imaging of 
hypoxia." 
Mai Xu, MD, PhD, "The 
effects of 41° hyperthermia 
on the DNA repair protein, 
MRE 11, correlate with 
radiosensitization in four 
human tumor cell lines." 
MEETING SUMMARY 
Eduardo Moros, PhD, 
"Highlights of physics/engi- 
neering presentations." 
POSTER PRESENTATIONS 
Bibianna Cha; Petr Novak, 
PhD; William Straube, MS; 
Robert Myerson, MD, PhD; 
Eduardo Moros, PhD, 
"Development of a Linac- 
SURLAS-patient interface 
transport." 
Bibianna Cha; Petr Novak, 
PhD; William Straube, MS; 
Robert Myerson, MD, PhD; 
Eduardo Moros, PhD, 
"Designing an articulated arm 
for the LINAC-SURLAS- 
patient interface transport." 
Andrei Laszlo, PhD, 
"Effects of heat shock on the 
state of phosphorylation of 
histone H2AX." 
Eduardo Moros, PhD, 
"Study of the hyperthermic 
effects of underlying bone on 
power and temperature pat- 
terns in tissue-like phantoms 
exposed to planar ultra- 
sound." 
Robert Myerson, MD, PhD, 
"Simultaneous radiation ther- 
apy and hyperthermia in the 
elective treatment of subclin- 
ical disease in high risk 
breast carcinoma: compari- 
son of post treatment normal 
tissue effects in heated and 
unheated portions of the 
chest wall"; "Modeling heat 
induced radiosensitization: 
clinical implications"; "Moni- 
toring the effect of 41°C 
hyperthermia on tumor 
hypoxia by Cu-ATSM PET 
scanning." 
Petr Novak, PhD; William 
Straube, MS; Bibianna 
Cha; Robert Myerson, MD, 
PhD; Eduardo Moros, 
PhD, "Preclinical evaluation 
of the SURLAS using a per- 
fused phantom;" 
Petr Novak, PhD; Anurag 
Singh, MD; Buck Rogers, 
PhD; Jacob Locke, MD; 
Andrea Zeug; William 
Straube, MS; Robert 
Myerson, MD, PhD; 
Eduardo Moros, PhD, 
"Performance of the SAHUS 
temperature controller in a 
perfused phantom and in- 
vivo experiments." 
Petr Novak, PhD; William 
Straube, MS; Bibianna 
Cha; Robert Myerson, MD, 
PhD; Eduardo Moros, 
PhD, "Software environment 
of the clinical SURLAS;" 
Petr Novak, PhD; William 
Straube, MS; Bibianna 
Cha; Robert Myerson, MD, 
PhD; Eduardo Moros, 
PhD, "Safety features of the 
clinical SURLAS." 
Petr Novak, PhD; Buck 
Rogers, PhD; Jacob Locke, 
MD; Anurag Singh, MD; 
Andrea Zeug; William 
Straube, MS; Robert 
Myerson, MD, PhD; 
Eduardo Moros, PhD, 
"Initial experience with the 
SAHUS—a small animal 
hyperthermia ultrasound 
system." 
Tej Pandita, PhD, 
"Genomic instability and 
enhanced radiosensitivity in 
Hsp70.1/3-deficient mice." 
Joseph Roti Roti, PhD, 
"Potential effects of short 
(1-5 second) thermoexpo- 
sures (+15 degree C) on 
DNA repair." 
William Straube, MS, "The| 
effect of hyperthermia appli- 
cators on radiation surface 
dose for simultaneous ther- 
moradiotherapy." 
Robert VanderWaal, PhD, I 
"Heat-shock induced overlap! 
of euchromatin and 
heterochromatin DNA 
replication." 
Mai Xu, MD, PhD, "The 
effects of 41° hyperthermia 
on the DNA repair protein, 
MRE 11, correlate with 
radiosensitization in four 
human tumor cell lines." 
Andrea Zeug; Dominic 
Thompson; Petr Novak, 
PhD; Kate Mazzerella; 
Eduardo Moros, PhD; 
Jacob Locke, MD, "Com 
parison of ultrasound versus | 
waterbath hyperthermia on 
HeLa xenografts." 
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Right: An actual human brain 
is included in the traveling 
exhibit, which is now at the 
Science Center in Kansas,. 
City, Missouri, through Sep- 
tember 11, 2004. 
Left: The PET III head scanner, one of the last 
scanners built on-site at the Institute, was 
part of Mallinckrodt Institute's contributions 
to the Science Center's focus on neurological 
research in St. Louis. When the traveling por- 
tion of the exhibit was taken to Kansas City, 
scanner was returned to its permanent 
e in the Scott Avenue Imaging Center. 
Above: The large, purple, alien-looking structures that 
made up the traveling brain exhibit at the St. Louis 
Science Center have moved on but, from January 31 
through May 2, they helped to explain the electro- 
magnetic workings and diseases occurring daily in our 
heads. Brain: The World Inside Your Head, produced 
by Pfizer Inc. in collaboration with the National Insti- 
tutes of Health, provided adults and children with fas- 
cinating information about the most complex structure 
in the known universe: the human brain. 
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